Tear cathepsin s as a candidate biomarker for sjögren's syndrome

Arthritis and Rheumatology

Volumn 66, Issue 7, 2014, Pages 1872-1881

  Hamm Alvarez, Sarah F ^a   Janga, Srikanth R ^a   Edman, Maria C ^a   Madrigal, Sara ^a   Shah, Mihir ^a   Frousiakis, Starleen E ^b   Renduchintala, Kavita ^b   Zhu, Jay ^b   Bricel, Seth ^b   Silka, Kimberly ^b   Bach, Dianne ^b   Heur, Martin ^b   Christianakis, Stratos ^b   Arkfeld, Daniel G ^b   Irvine, John ^b   Mack, Wendy J ^b   Stohl, William ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN S; TEAR PROTEIN;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BLEPHARITIS; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRY EYE; ENZYME ACTIVITY; FEMALE; HUMAN; LACRIMAL FLUID; LACRIMAL GLAND; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RELIABILITY; RHEUMATOID ARTHRITIS; SCHIRMER STRIP; SCHIRMER TEST; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ANIMALS; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; BLEPHARITIS; CATHEPSINS; DIAGNOSIS, DIFFERENTIAL; DRY EYE SYNDROMES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NOD; MIDDLE AGED; SJOGREN'S SYNDROME; TEARS;

EID: 84903456552     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38633     Document Type: Article

References (52)

1. Fox RI, Kang HI,. Pathogenesis of Sjogren's syndrome. Rheum Dis Clin North Am 1992; 18: 517-38.
2. Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y,. Sjögren's syndrome, the old and the new. Best Pract Res Clin Rheumatol 2012; 26: 105-17.
3. Voulgarelis M, Tzioufas AG, Moutsopoulos HM,. Mortality in Sjögren's syndrome. Clin Exp Rheumatol 2008; 26 (5 Suppl 51): S66-71.
4. Anderson LG, Talal N,. The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome. Clin Exp Immunol 1972; 10: 199-221.
5. Launay D, Hachulla E, Hatron PY, Jais X, Simonneau G, Humbert M,. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007; 86: 299-315.
6. Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM,. Sjogren's syndrome: why autoimmune epithelitis? Oral Dis 2006; 12: 523-32.
7. Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH,. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; 130: 1489-95.
8. Soy M, Piskin S,. Cutaneous findings in patients with primary Sjogren's syndrome. Clin Rheumatol 2007; 26: 1350-2.
9. Porola P, Laine M, Virkki L, Poduval P, Konttinen YT,. The influence of sex steroids on Sjögren's syndrome. Ann N Y Acad Sci 2007; 1108: 426-32.
10. Whitcher JP,. Clinical diagnosis of the dry eye. Int Ophthalmol Clin 1987; 27: 7-24.
11. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
12. Richards A, Mutlu S, Scully C, Maddison P,. Complications associated with labial salivary gland biopsy in the investigation of connective tissue disorders. Ann Rheum Dis 1992; 51: 996-7.
13. Baldini C, Talarico R, Tzioufas AG, Bombardieri S,. Classification criteria for Sjogren's syndrome: a critical review. J Autoimmun 2012; 39: 9-14.
14. Vitali C, Bootsma H, Bowman SJ, Dorner T, Gottenberg JE, Mariette X, et al. Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis 2013; 72: 476-8.
15. Burbelo PD, Ching KH, Issa AT, Loftus CM, Li Y, Satoh M, et al. Rapid serological detection of autoantibodies associated with Sjogren's syndrome. J Transl Med 2009; 7: 83.
16. Li X, Wu K, Edman M, Schenke-Layland K, MacVeigh-Aloni M, Janga SR, et al. Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse. Invest Ophthalmol Vis Sci 2010; 51: 5019-29.
17. Nguyen CQ, Sharma A, She JX, McIndoe RA, Peck AB,. Differential gene expressions in the lacrimal gland during development and onset of keratoconjunctivitis sicca in Sjögren's syndrome (SJS)-like disease of the C57BL/6.NOD-Aec1Aec2 mouse. Exp Eye Res 2009; 88: 398-409.
18. Goldblatt F, O'Neill SG,. Clinical aspects of autoimmune rheumatic diseases. Lancet 2013; 382: 797-808.
19. Alarcon GS, Williams GV, Singer JZ, Steen VD, Clegg DO, Paulus HE, et al. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. J Rheumatol 1991; 18: 1332-9.
20. Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, et al. Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum 2007; 56: 3588-600.
21. Pink R, Simek J, Vondrakova J, Faber E, Michl P, Pazdera J, et al. Saliva as a diagnostic medium. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153: 103-10.
22. Shi GP, Munger JS, Meara JP, Rich DH, Chapman HA,. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem 1992; 267: 7258-62.
23. Shi GP, Villadangos JA, Dranoff G, Small C, Gu L, Haley KJ, et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 1999; 10: 197-206.
24. Shi GP, Webb AC, Foster KE, Knoll JH, Lemere CA, Munger JS, et al. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem 1994; 269: 11530-6.
25. Wolters PJ, Chapman HA,. Importance of lysosomal cysteine proteases in lung disease. Respir Res 2000; 1: 170-7.
26. Riese RJ, Wolf PR, Bromme D, Natkin LR, Villadangos JA, Ploegh HL, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996; 4: 357-66.
27. Lotteau V, Teyton L, Peleraux A, Nilsson T, Karlsson L, Schmid SL, et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990; 348: 600-5.
28. Beers C, Burich A, Kleijmeer MJ, Griffith JM, Wong P, Rudensky AY,. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo. J Immunol 2005; 174: 1205-12.
29. Nguyen CQ, Peck AB,. Unraveling the pathophysiology of Sjogren syndrome-associated dry eye disease. Ocul Surf 2009; 7: 11-27.
30. Conus S, Simon HU,. Cathepsins and their involvement in immune responses. Swiss Med Wkly 2010; 140: w13042.
31. Saegusa K, Ishimaru N, Yanagi K, Arakaki R, Ogawa K, Saito I, et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest 2002; 110: 361-9.
32. Reddy VY, Zhang QY, Weiss SJ,. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc Natl Acad Sci U S A 1995; 92: 3849-53.
33. Baugh M, Black D, Westwood P, Kinghorn E, McGregor K, Bruin J, et al. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun 2011; 36: 201-9.
34. Brix K, Dunkhorst A, Mayer K, Jordans S,. Cysteine cathepsins: cellular roadmap to different functions. Biochimie 2008; 90: 194-207.
35. Goeb V, Salle V, Duhaut P, Jouen F, Smail A, Ducroix JP, et al. Clinical significance of autoantibodies recognizing Sjogren's syndrome A (SSA), SSB, calpastatin and α-fodrin in primary Sjogren's syndrome. Clin Exp Immunol 2007; 148: 281-7.
36. Shen L, Suresh L, Lindemann M, Xuan J, Kowal P, Malyavantham K, et al. Novel autoantibodies in Sjogren's syndrome. Clin Immunol 2012; 145: 251-5.
37. Tzioufas AG, Tatouli IP, Moutsopoulos HM,. Autoantibodies in Sjogren's syndrome: clinical presentation and regulatory mechanisms. Presse Med 2012; 41 (9 Pt 2): e451-60.
38. Kramer JM, Klimatcheva E, Rothstein TL,. CXCL13 is elevated in Sjögren's syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol 2013; 94: 1079-89.
39. Li YN, Guo JP, He J, Liu X, Yin FR, Ding Y, et al. Serum IgA against type 3 muscarinic acetylcholine receptor is a novel marker in diagnosis of Sjogren's syndrome. Chin Med J 2011; 124: 2490-5.
40. Kitagawa T, Shibasaki K, Toya S,. Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjogren's syndrome. Clin Rheumatol 2012; 31: 105-12.
41. Kroese FG, Bootsma H,. Biomarkers: new biomarker for Sjogren's syndrome-time to treat patients. Nat Rev Rheumatol 2013; 9: 570-2.
42. Maria NI, Brkic Z, Waris M, van Helden-Meeuwsen CG, Heezen K, van de Merwe JP, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome. Ann Rheum Dis 2013, doi:pii: annrheumdis-2012-202552v1. 10.1136/annrheumdis-2012-202552.
43. Tobon GJ, Saraux A, Gottenberg JE, Quartuccio L, Fabris M, Seror R, et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 2013; 65: 3218-27.
44. Gottenberg JE, Seror R, Miceli-Richard C, Benessiano J, Devauchelle-Pensec V, Dieude P, et al. Serum levels of β2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome: data at enrollment in the prospective ASSESS cohort. PloS One 2013; 8: e59868.
45. Hu S, Vissink A, Arellano M, Roozendaal C, Zhou H, Kallenberg CG, et al. Identification of autoantibody biomarkers for primary Sjogren's syndrome using protein microarrays. Proteomics 2011; 11: 1499-507.
46. Hu S, Gao K, Pollard R, Arellano-Garcia M, Zhou H, Zhang L, et al. Preclinical validation of salivary biomarkers for primary Sjogren's syndrome. Arthritis Care Res 2010; 62: 1633-8.
47. Da Costa SR, Wu K, Veigh MM, Pidgeon M, Ding C, Schechter JE, et al. Male NOD mouse external lacrimal glands exhibit profound changes in the exocytotic pathway early in postnatal development. Exp Eye Res 2006; 82: 33-45.
48. Haga HJ,. Clinical and immunological factors associated with low lacrimal and salivary flow rate in patients with primary Sjogren's syndrome. J Rheumatol 2002; 29: 305-8.
49. Vissink A, Bootsma H, Kroese FG, Kallenberg CG,. How to assess treatment efficacy in Sjogren's syndrome? Curr Opin Rheumatol 2012; 24: 281-9.
50. Von Thun Und Hohenstein-Blaul N, Funke S, Grus FH,. Tears as a source of biomarkers for ocular and systemic diseases. Exp Eye Res 2013; 117: 127-37.
51. Zhou L, Beuerman RW,. Tear analysis in ocular surface diseases. Prog Retin Eye Res 2012; 31: 527-50.
52. Tomosugi N, Kitagawa K, Takahashi N, Sugai S, Ishikawa I,. Diagnostic potential of tear proteomic patterns in Sjogren's syndrome. J Proteome Res 2005; 4: 820-5.